Maxim Group Keeps a Buy Rating on VistaGen Therapeutics (VTGN)

Maxim Group analyst Jason McCarthy maintained a Buy rating on VistaGen Therapeutics (VTGNResearch Report) yesterday and set a price target of $4.00. The company’s shares closed last Monday at $1.11.

According to, McCarthy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -24.2% and a 22.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Inc., Hancock Jaffe Laboratories Inc, and Aridis Pharmaceuticals Inc.

Currently, the analyst consensus on VistaGen Therapeutics is a Moderate Buy with an average price target of $3.90.

See today’s analyst top recommended stocks >>

Based on VistaGen Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $6.21 million. In comparison, last year the company had a GAAP net loss of $7.44 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.